Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Lymphoma Clinical Trial

Official title:

A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00589563
• Other study ID #: 06141
• Secondary ID: P30CA033572CHNMC
• Status: Completed
• Phase: Phase 2
• First received: December 21, 2007
• Last updated: September 3, 2014
• Start date: May 2007
• Est. completion date: February 2012

Study information

• Verified date: September 2014
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer .

Description:

OBJECTIVES:

Primary

• To determine the incidence and severity of acute- and chronic-graft-versus-host disease (GVHD) after HLA-matched or -mismatched unrelated donor hematopoietic peripheral blood transplantation in patients with hematologic malignancies scheduled to receive immunosuppressive combination of sirolimus, tacrolimus, and anti-thymocyte globulin as GVHD prophylaxis.

• To determine the safety of this combination in the first six months post-transplant.

Secondary

• To determine the time-to-engraftment, non-relapse mortality rate, overall and disease-free survival, incidence of disease relapse, and incidence of opportunistic infections with this GVHD prophylaxis.

OUTLINE: Patients are stratified according to conditioning regimen (fludarabine phosphate and melphalan vs fractionated total-body irradiation [FTBI] and etoposide vs FTBI and cyclophosphamide) and degree of donor/recipient HLA mismatch (high-risk vs low-risk).

• Conditioning regimen: Patients receive 1 of 3 standard conditioning regimens beginning on day -9 or -8 and continuing to day -1 or 0.

• Peripheral blood stem cell transplantation: Patients receive HLA-matched or mismatched unrelated donor peripheral blood stem cells on day 0.

• Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV continuously beginning on day -3 and then orally when tolerated, oral sirolimus on days -3 and -2, anti-thymocyte globulin IV over 4-8 hours on days -3 to 0, and methotrexate* IV on days 1, 3, and 6. Tacrolimus and sirolimus continue for 3-6 months (with taper).

NOTE: *Only patients with high-risk HLA mismatch receive treatment with methotrexate.

After completion of study therapy, patients are followed periodically for up to 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of hematological malignancy including any of the following:

• Non-Hodgkin lymphoma (NHL) in any complete remission (CR) or partial response (PR)

• Hodgkin lymphoma in any CR or PR

• Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in any CR

• Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation of conditioning for patients with non-CR AML or ALL

• Myelodysplastic syndromes (MDS) treated or untreated

• Chronic myelogenous leukemia (CML) in chronic or accelerated phase

• Multiple myeloma in any CR or PR

• Chronic lymphocytic leukemia in CR or PR 2 or greater

• Myelofibrosis and other myeloproliferative disorders

• Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation

• High-risk disease defined as AML or ALL > CR1, accelerated phase CML, recurrent aggressive lymphoma, or active lymphoproliferative disease at transplant

• Low-risk disease defined as AML or ALL in CR1, chronic phase CML, or low-grade lymphoproliferative disorder with controlled disease at transplant

• Must be planning to receive 1 of the following conditioning regimens at City of Hope:

• Fludarabine phosphate and melphalan for patients with hematological malignancies and contraindications for conventional myeloablative regimens due to age, co-morbidity, or previous transplant

• Fractionated total-body irradiation (FTBI) and etoposide for patients with AML and ALL or CML in accelerated phase

• FTBI and cyclophosphamide for patients with NHL, AML, CML, and MDS

• Suitable unrelated donor available

• HLA-matched or mismatched

• Peripheral blood stem cells available

• No bone marrow or ex vivo-engineered or processed graft (e.g., CD34-positive, T-cell depletion)

• No uncontrolled CNS disease

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) 70-100% or ECOG PS 0-2

• Creatinine < 1.3 mg/dL or creatinine clearance = 70 mL/min

• Ejection fraction > 45%

• Direct bilirubin < 3 times upper limit of normal (ULN)

• ALT and AST < 3 times ULN

• Forced vital capacity, FEV1, and DLCO > 45% of predicted

• Able to cooperate with oral medication intake

• No active donor or recipient serology positive for HIV

• No known contraindication to administration of sirolimus, tacrolimus, or anti-thymocyte globulin

• No active hepatitis B or C

• Negative pregnancy test

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Concurrent participation in other clinical trials for prevention or treatment of viral, bacterial, or fungal disease allowed provided agents do not interact with agents used in the current study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Chronic Myeloproliferative Disorders
• Graft Versus Host Disease
• Graft vs Host Disease
• Infection
• Leukemia
• Lymphoma
• Multiple Myeloma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Neoplasms
• Myeloproliferative Disorders
• Neoplasms
• Neoplasms, Plasma Cell
• Plasmacytoma
• Precancerous Condition
• Precancerous Conditions
• Preleukemia
• Primary Myelofibrosis
• Secondary Myelofibrosis
• Small Intestine Cancer

Intervention

Biological:
• anti-thymocyte globulin
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant

Drug:
• cyclophosphamide
60mg/kg on days -5 and -4 from stem cell transplant
• etoposide
60mg/kg on day -4 from stem cell transplant
• fludarabine phosphate
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
• melphalan
Melphalan 140 mg/m2 on day -4 from stem cell transplant
• methotrexate
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
• sirolimus
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
• tacrolimus
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant

Procedure:
• allogeneic hematopoietic stem cell transplantation
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
• hematopoietic stem cell transplantation
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
• nonmyeloablative allogeneic hematopoietic stem cell transplantation
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
• peripheral blood stem cell transplantation
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight

Radiation:
• total-body irradiation
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant

Locations

Country	Name	City	State
United States	City of Hope Comprehensive Cancer Center	Duarte	California
United States	Banner Good Samaritan Medical Center	Phoenix	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100	Patients were evaluated for the development of acute GVHD within the first 100 days post HSCT. The cumulative incidence of grade II-IV acute GVHD was determined using competing risk analysis. Competing risks for acute GVHD were death and nonengraftment.	100 Days Post Hematopoietic Stem Cell Transplant (HSCT)	No
Primary	Severity of Acute GVHD	All patients were considered for the evaluation of the severity of acute GVHD.	100 Days Post HSCT	No
Primary	Cumulative Incidence of Chronic GVHD	Patients were evaluated for the development of chronic GVHD from 101 days post HSCT to last contact or documented evidence of the disease. The cumulative incidence of chronic GVHD was determined using competing risk analysis. Competing risks for GVHD were death and nonengraftment.	2 year point estimate was provided.	No
Primary	Severity of Chronic GVHD	All Patients were considered for the evaluation of chronic GVHD severity.	Patients were evaluated until they developed chronic GVHD, a median of 130 days post HSCT	No
Secondary	Time to Absolute Neutrophil Count Recovery (Engraftment)	Absolute neutrophil count (ANC) recovery is defined as an ANC of = 0.5 x 10^9/L (500/mm3) for three consecutive laboratory values obtained on different days	Patients were evaluated until neutrophil recovery, a median of 15 days post HSCT	Yes
Secondary	Time to Platelet Count Recovery (Engraftment)	Platelet recovery is defined as the first date of three consecutive laboratory values = 25 x 10^9 L obtained on different days.	Patients were evaluated until platelet recovery, a median of 14 days	Yes
Secondary	Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation	Participants were monitored throughout the trial (median of 28 months) for various infections/complications.	Median Follow Up: 28 months (Range: 1-49 months)	Yes
Secondary	Occurrence of Thrombotic Microangiopathy	Participants were monitored throughout the trial (median of 28 months) for various infections/complications. This is the number of participants who developed TMA.	Median Follow Up: 28 Months (Range: 1-49 months)	Yes
Secondary	Occurence of Sinusoidal Obstructive Syndrome (SOS)	Participants were monitored throughout the trial (median of 28 months) for various infections/complications. This is the number of participants who developed SOS.	Median Follow Up: 28 Months (Range: 1-49 Months)	Yes
Secondary	Non-relapse Mortality at 100 Days Post HSCT	Patients were evaluated for non-relapse mortality (NRM) throughout the study. Non-relapse mortality was considered any death not attributable to relapse or disease progression. The cumulative incidence of NRM was determined using competing risk analysis. Competing risks for NRM were death due to disease progression, relapse and nonengraftment.	100 day point estimate was provided	Yes
Secondary	Non-relapse Mortality at Two Years Post HSCT	Patients were evaluated for non-relapse mortality (NRM) throughout the study. Non-relapse mortality was considered any death not attributable to relapse or disease progression. The cumulative incidence of NRM was determined using competing risk analysis. Competing risks for NRM were death due to disease progression, relapse and nonengraftment.	2 year point estimate was provided.	No
Secondary	Overall Survival at Two Years Post HSCT	Patients were evaluated for survival (OS) throughout the study. Kaplan Meier estiamtes were calculated for overall survival using time from HSCT to death of any cause or for surviving patients last contact date.	2 year point estimate was provided.	No
Secondary	Event Free Survival at Two Years Post HSCT	Patients were evaluated for event free survival (EFS) throughout the study. Events were defined as death, relapse, progression, or nonengraftment. Kaplan Meier estimates were calculated as time from HSCT to event.	2 year point estimate was provided.	No
Secondary	Incidence of Disease Relapse/Progression at 2 Years Post HSCT	Patients were evaluated for relapse/progression post transplant throughout the study. The cumulative incidence of relapse/progression was determined using competing risk analysis. Competing risks for relapse were non-relapse mortality and nonengraftment.	2 year point estimate was provided.	No